Mabion S.A.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2009-10-29
Share capital
1,616,232.60 PLN
Activity description

Mabion is a European contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, including drug substance manufacturing, analytics, and fill & finish processes. The company offers end-to-end development services from gene to vial, as well as cell line development and banking. Mabion collaborates with various pharmaceutical companies on projects such as the development of antibody-drug conjugates (ADCs) and analytical method development.

Registered address
ul. Gen. Mariana Langiewicza 60, 95-050 Konstantynów Łódzki, Poland
Website
Email
Phone
Social media
Electronic delivery address
AE:PL-16721-85010-DWWCR-09

Financials

Revenue history (in m)

Filing timeliness

Financial statements were filed on time, on average 37 days early. All were audited by a statutory auditor.

  • 202526/06/2026
  • 202409/06/2025
  • 202325/06/2024
  • 202220/06/2023
  • 202127/06/2022
  • 202002/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Sanctions and PEP lists

PersonList
Józef Antoni BanachCzłonek organu spółki Skarbu Państwa

Stock quotes

PLN 9.40
-0.04 (-0.42%)
9.309.409.509.609.4010:0012:0014:0016:00
Open
PLN 9.47
High
PLN 9.58
Low
PLN 9.26
Volume
33.08K
Avg. vol.
207.97K
Market cap
PLN 151.93M
P/E ratio
–
EPS
-PLN 3.50
Shares outstanding
16.16M
52-week
PLN 7.68 – 11.22
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q2 2026USD 881.42kUSD -3.73mUSD -4.03m
Q1 2026USD 1.23mUSD -2.48mUSD -2.63m
Q4 2025USD 1.43mUSD -5.06mUSD -5.32m
Q3 2025USD 1.03mUSD -2.69mUSD -2.70m

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 9.5%
Top 5.4%
City · Konstantynów Łódzki32 / 153
Top 21%
Voivodeship · Łódzkie2,173 / 15,341
Top 14%
Country · Poland40,156 / 297,566
Top 13%

Results vs industry

Revenue
This companyUSD 3.86mMedianUSD 153.26kAverageUSD 4.77m
Net profit
This companyUSD -15.72mMedianUSD -293.45AverageUSD 307.82k
Operating costs
This companyUSD 16.87mMedianUSD 188.47kAverageUSD 4.59m
Assets
This companyUSD 27.73mMedianUSD 281.58kAverageUSD 8.35m

Trademarks

The company holds 1 active trademark registered with the Polish Patent Office. 1 mark has expired or was not registered. The first mark was filed in 2010.

MarkNumberClassesStatusProtected until
MABION (word)Z.3758505Protected Sep 28, 2030
mabion people and ideas of biotech Z.3817005Proceedings discontinued –
MarkProtected until
MABION (word)Sep 28, 2030
mabion people and ideas of biotech –

Authorized Representatives

Detlef Behrens – Management Board Member
Joaquín Santos-Benito – Management Board Member
Gregor Kawaletz – President of the Management Board

Manner of representation

The following are authorized to make declarations of will on behalf of the company: two members of the management board acting jointly or one member of the management board acting jointly with a commercial proxy.

Supervisory board

Józef Antoni Banach age 55 – Supervisory Board Member
Mateusz Rosa-Gawałkiewicz age 38 – Supervisory Board Member
Robert Koński age 60 – Supervisory Board Member
Przemysław Mencel age 55 – Supervisory Board Member
Wojciech Wośko age 60 – Supervisory Board Member

Beneficial owners

Mabion is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.

Bank accounts

Registered as a VAT taxpayer on 2007-06-01.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Jan 15, 2025Bankruptcy notice
Jan 22, 2020Bankruptcy sale
Nov 2, 2018Bankruptcy notice
Jun 7, 2010Shareholders' meeting convened
Mar 26, 2010Shareholders' meeting convened

Public aid

15 public aid cases recorded, with a total value of $19,962,995.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
De minimis aid (in accordance with Commission Regulation 2023/2831)
–

European Funds

ProjectEU co-financing
Development of a panel of analytical methods to characterize immunogenicity in a clinical trial for patients suffering from rheumatoid arthritis using rituximab as the medicinal substance.
$538.4K
Development of a biotechnological drug through the development of an innovative IgG1-subclass monoclonal antibody with a reduced content of undesirable glycoforms compared with the reference drug, targeting EGFR
$7.4M
Development and scaling of an innovative process for manufacturing a therapeutic recombinant monoclonal antibody to enable the industrial implementation of the first Polish biotechnological drug for oncological and autoimmune therapies.
$6.8M

Regulatory authorisations

AuthorityTypeStatus
Integrated permit Active

Competitors

Name
Przedsiębiorstwo Produkcyjno-Handlowe Ewa S.A.
Medicofarma S.A.
Nutramatic sp. z o.o.
Hemplab sp. z o.o.
Ever Pharma Poland sp. z o.o.
Elanda Pharma sp. z o.o.
Bioactive T sp. z o.o.
Grand Medical Poland sp. z o.o.
COS Lab P.S.A.
Celltrion Poland sp. z o.o.

Change history

DateEvent
2022-11-29Share capital increase
2022-04-20Share capital increase
2021-04-02Share capital increase
2020-06-18Share capital increase
2018-04-30Share capital increase

FAQ

Last updated: 2026-08-10